Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers

Xenobiotica

Volumn 39, Issue 7, 2009, Pages 514-522

  Aleksunes, L M ^a   Yeager, R L ^a   Klaassen, C D ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine triphosphate binding cassette subfamily C (ABCC); Constitutive androstane receptor (CAR); Hepatocyte nuclear factor 1 alpha (HNF1 ); Peroxisome proliferator activated receptor alpha (PPAR ); Transporters

Indexed keywords

ANDROSTANE RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; FARNESOID X RECEPTOR; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; RETINOID X RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ABCC4 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LIVER; MALE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; ADOLESCENT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 70349573920     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902952514     Document Type: Article

References (32)

1. Aleksunes LM, Slitt AL, Maher JM, Augustine LM, Goedken MJ, Chan JY, Cherrington NJ, Klaassen CD, Manautou JE. (2008). Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol 226:74-83.
2. Auerbach SS, Ramsden R, Stoner MA, Verlinde C, Hassett C, Omiecinski CJ. (2003). Alternatively spliced isoforms of the human constitutive androstane receptor. Nucl Acid Res 31:3194-3207
3. Cereghini S. (1996). Liver-enriched transcription factors and hepatocyte differentiation. FASEB J 10:267-282
4. De la Fuente A, Bing N, Hoeschele I, Mendes P. (2004). Discovery of meaningful associations in genomic data using partial correlation coefficients. Bioinformatics 20:3565-3574
5. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE. (2005). Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 54:582-586
6. Fukushima-Uesaka H, Saito Y, Maekawa K, Hasegawa R, Suzuki K, Yanagawa T, Kajio H, Kuzuya N, Noda M, Yasuda K, Tohkin M, Sawada J. (2007). Genetic variations of the ABC transporter gene ABCC3 in a Japanese population. Drug Metab Pharmacokinet 22:129-135
7. Gonzalez FJ, Shah YM. (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2-8.
8. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. (2003). Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100:4156-4161
9. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT. (2000). The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39.
10. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915
11. Klaassen CD, Slitt AL. (2005). Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6:309-328
12. Kohle C, Bock KW (2007). Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 73:1853-1862
13. Lagas JS, Vlaming ML, Van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, Schinkel AH. (2006). Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 12:6125-6132
14. Lee YM, Cui Y, Konig J, Risch A, Jager B, Drings P, Bartsch H, Keppler D, Nies AT. (2004). Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14:213-223
15. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD. (2008). Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106:319-328
16. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. (2005). Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33:956-962
17. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y, Dalton TP, Yamamoto M, Klaassen CD. (2007). Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 46:1597-1610
18. Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. (2006). Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol 72:512-522
19. Manautou JE, De Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. (2005). Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098
20. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. (2006). Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44:62-74.
21. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, Boyer JL. (2006). Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43:1013-1021
22. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. (2006). Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J Pharmacol Exp Ther 317:537-545
23. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA. (2004). Control of pancreas and liver gene expression by HNF transcription factors. Science 303:1378-1381
24. Ringeisen F, Rey-Campos J, Yaniv M. (1993). The transactivation potential of variant hepatocyte nuclear factor 1 is modified by alternative splicing. J Biol Chem 268:25706-25711
25. Schrem H, Klempnauer J, Borlak J. (2002). Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev 54:129-158
26. Slitt AL, Allen K, Morrone J, Aleksunes LM, Chen C, Maher JM, Manautou JE, Cherrington NJ, Klaassen CD. (2007). Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim Biophys Acta 1768:637-647
27. Van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, Borst P. (2007). Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394
28. Vlaming ML, Mohrmann K, Wagenaar E, De Waart DR, Elferink RP, Lagas JS, Van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327
29. Wang H, LeCluyse EL. (2003). Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42:1331-1357
30. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ. (2007). Expression of constitutive androstane receptor, hepatic nuclear factor 4{alpha}, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710
31. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, Brouwer KL. (2006). Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491
32. Zelcer N, Van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. (2005). Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 102:7274-7279